Operator's Information

Eberhard Grube, MD

Country Germany
Specialty Interventional Cardiologist
  1. Essentials of Lifetime Management of Aortic Disease: Updated and Novel Points in 2024
  2. AS Lifetime Management
  3. EVOLUT: New Trials, New Technologies (OPTIMIZE PRO and SMART)
  4. TAVR is Better
  5. How to Prevent TAVR Complications with New TAVR Devices
  6. Next Innovation in Transcatheter Valve Intervention: New Techniques and New Valves
  7. Optimal TAVR Procedure for Bicuspid AV: Self Expandable Device
  8. Novel Implant Techniques: What is Different?
  9. Minimizing Embolic Events: Latest TAVR Data
  10. The Next Target of the Valvular Intervention: Future Perspectives
  11. Mitral Valve-in-Valve and Valve-in-Ring: Outcomes and Procedural Considerations
  12. Percutaneous Mitral Valve Repair: Current Status and Future Perspectives
  13. Future Perspectives for TAVR - What Is Remained?
  14. TAVR in 2019: Appropriate Patient and Device Selection
  15. Evolut PRO Latest Innovation in TAVI: A Workhorse Device to Treat All Patient
  16. Cerebral Protection in TAVR: Which Patient Category or Anatomical Subset?
  17. Next Generation TAVR Devices
  18. TAVR Will Be a New Standard Even for Low-risk Patients
  19. Cerebral Embolic Protection: Routine or Selective
  20. MitraClip and TMVR Complications and Failures
  21. Cerebral Protection Device During TAVI: State of the Art
  22. TAVR vs SAVR in 2018: Updated Guidelines and Appropriate Use Criteria
  23. Rapid Changing TAVR Story: Predicting the Future from Ongoing TAVR Clinical Trials
  24. European Registry
  25. Severe Calcification: Avoid or Overcome
  26. Coronary or Cerebral Protection: When and How?
  27. Complex TAVR for Specific Challenging Cases - How to Do in Practice?
  28. New Mainstream TAVR
  29. TAVR of High-Risk/Complex Patients: For Whom and with?
  30. Building Evidence for Treating Lower Risk Patients: Recent Updates From Evolut R Technology and Evidence
  31. [Featured Lecture] \"TAVI Perspective 2017: Current Situation - Controversy - Prospect\"
  32. SURTAVI: Step-by-Step Moving Forward to Low Risk and Younger Patients
  33. Evolut R
  34. Ongoing TAVR Trials and Updating TAVR Guidelines
  35. Cerebral Embolic Protection During TAVR
  36. Update on Medtronic Intrepid Transcatheter Mitral Valve Replacement
  37. Monitoring Conduction Disturbance and Avoiding Permanent Pacemaker
  38. TAVR in Lower Risk
  39. Evolut R
  40. Evolving Trends in Complications After TAVR
  41. How Evolut R Has Impacted My Practice?
  42. Mechanical Expanded Lotus Valve
  43. Do We Need a Dedicated Bifurcation Stent or Is This a Niche Device?
  44. Next Generation Valve System Addressing Current TAVR Limitations
  45. Why I Select Self Expandable Valve.
  46. Valve in Valve Implants for Failed Bioprosthetic Heart Valves
  47. Ultimate Comparison: Sapien vs. Corevalve
  48. Which TAVI Devices to Use: A Multi-Device Patient-Specific Approach
  49. Stroke Prevention: When and How
  50. Boston Lotus: Transfemoral
  51. Beyond the First-generation Devices
  52. European Registry: Sapien vs. Core
  53. New TAVI Devices
  54. Beyond High-risk Patients: Will TAVR Replace Surgical AVR?
  55. Registry Results of Self-expandable CoreValve Studies
  56. Dedicated Bifurcation Stent
  57. New TAVI Systems
  58. Medtronic: CoreValve Evolut and Engager TAVI System
  59. European Outcomes of CoreValve Registry
  60. Durability of Sapien Valve and CoreValve
  61. Taped Lives: Implantation of CoreValve, Transaxilla or Transaortic
  62. Technology and Procedural Changes
  63. Core Valve Enough !
  64. Upcoming New Devices
  65. Alternative Approach with Core Valve: Transaxillary and Others
  66. Implantation: Rapid Pacing, Pre-and Post-dilation
  67. Taped Live Case: Core Valve 2
  68. TAVI; Evidence, Controversy, Complications, and Future Perspective
  69. Invited Case Presentation & Focus Review: Aortic Valve Intervention(Core Valve)
  70. Taking DES Technology from Concept to Clinical Proof
  71. Which One Is Better?- Edwards or CoreValve or Others?: CoreValve Is Better!
  72. Valve-in-Valve TAVI
  73. Case Selection for TAVR: Beyond the High-risk Patient
  74. Evidence Based Medicine: Does BioMatrixTM Bring Patient Benefit? - 3 Yr/Subgroup Follow Up from LEADERS Trial
  75. Case Presentation of the First Restenosed Core Valve Prosthesis: Treatment Solution!
  76. BIOFREEDOM: Polymer-Free Biolimus A9-Eluting Stents and Paclitaxel-Eluting Stents
  77. Incidence and Treatment of Procedural Complications
  78. TAVI Perspectives from the European Theatre: New Indications and Multiple Devices
  79. Pitfalls During the TAVI (Core Valve) Implantation and How to Treat Them\".
  80. Dedicated Bifurcation and Left Main Stents
  81. An Update of the Self Expanding Medtronic/Core Valve TAVI
  82. The Core Valve Experience from the Siegburg Heart Center. An Update.
  83. New TAVI Devices: More of the Same or Meaningful Differences?
  84. Next Generation on PAVR Technologies
  85. New Approach to Treating Thrombus- Containing Lesions
  86. Interventionalist Perspective: The Treatment Pathway Was Shifted !
  87. New Stent Platforms
  88. Update on the Core Valve Experience
  89. The Future Landscape of DES: New Stent Platforms, Drug Carriers, and Recent FIM Experiences
  90. Percutaneous Aortic Valve Implantation
  91. Drug Eluting Stents (Bifurcation and Left Main Approach)
  92. The Xtent™ DES System: The Single Solution for Multilesion, Multivessel, and Long Lesion Treatment
  93. Biolimus A9 Drug-Eluting Stents: Technical Aspects and a Comprehensive Review of the EU, Asia-Pacific, and US NOBORI Clinical Trial Program
  94. Current Data Indicates No Clinically Relevant Differences Between CYPHER and TAXUS!
  95. Everolimus Drug-Eluting Stents I: Review of Guidant FUTURE I and II, and Status Update of FUTURE III and IV
  96. The Biolimus A9 DES Program (Focus on Stealth 1)
  97. Is the TAXUS Stent Benefit Extended to the Most Complicated Patients and Lesions?
  98. New Drug-Eluting Stents: Everolimus (FUTURE-I and -II) and More
Conference Slides
Category